Reshma Kewalramani sold $19.7M of Vertex Pharmaceuticals Incorporated (VRTX)

Executed Feb 27, disclosed Mar 3, 4 days later.

Value, as filed

$19.7M

39,880 sh across 12 lots

Executed

Feb 27

the trade date, as filed

Disclosed

Mar 3

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

RK Reshma Kewalramani CEO & President profile →

Reshma Kewalramani (CEO & President) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $19.7M of VRTX (39,880 sh across 12 lots, as filed), executed Feb 27.

The name

VRTX Vertex Pharmaceuticals Incorporated VRTX · Healthcare · 90 filings in 24 months ticker →

Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Reshma Kewalramani in VRTX

VRTXPURCHASE Vertex Pharmaceuticals Incorporated $3.9M
10,000 sh across 2 lots
Exec Aug 6 2025
Filed Aug 7 2025 · 4:23 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated $7.8M
15,198 sh × $515.00
Exec Nov 8 2024
Filed Nov 12 2024 · 5:30 PM ET